# Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

> **NCT03822858** · — · AVAILABLE · sponsor: **Tisch Multiple Sclerosis Research Center of New York**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Intrathecal MSC-NP injection

## Key facts

- **NCT ID:** NCT03822858
- **Lead sponsor:** Tisch Multiple Sclerosis Research Center of New York
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822858, "Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03822858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*